Podcasts about anticoagulants

keywords:   wisdom teeth, dental myths, bone grafts, dry sockets, anticoagulants, sedation, marijuana, dental procedures, oral surgery, dental care, Dr. Wahan. Dr. Tomsic, Serv Wahan, Jaclyn Tomsic, Mythbusters, Myths, Dental myths     summary:   In this conversation, Dr. Serv Wahan and Dr. Jaclyn Tomsic discuss various myths and misconceptions surrounding dental practices, particularly focusing on wisdom teeth, bone grafts, dry sockets, and the impact of medications on dental procedures. They explore the reasons behind wisdom teeth removal, the realities of bone grafting, and the effects of smoking and anticoagulants on dental health. The discussion also touches on the influence of marijuana use on sedation and the prevalence of dental myths in social media. The conversation concludes with a rapid-fire segment addressing common dental myths.     takeaways: Wisdom teeth removal is not always necessary for everyone. Bone grafts serve as scaffolds but do not grow. Dry sockets can be influenced by smoking and age. Anticoagulants should not be stopped before dental procedures without medical advice. Marijuana use can complicate sedation during dental procedures. Charcoal toothpaste is too abrasive for regular use. Oil pulling lacks proven benefits for dental health. Pineapple juice may help reduce inflammation post-surgery, but is not a cure-all. Patients often confuse novocaine with modern anesthetics. Telehealth and DIY dental solutions can pose risks to patients.   titles: Debunking Dental Myths: Wisdom Teeth and Beyond The Truth About Wisdom Teeth: Myths vs. Facts   Sound Bites: "Why'd you take those out?" "Bone grafts don't grow." "Marijuana causes more anxiety?"   Chapters: 00:00 Introduction and Overview of Myths 00:36 Wisdom Teeth: Myths and Realities 09:24 Bone Grafts: Understanding the Myths 09:52 Socket Healing and Complications 15:38 Anticoagulants and Dental Extractions 26:14 Managing Post-Operative Bleeding 29:31 Anticoagulants and Their Impact 30:49 The Role of Marijuana in Sedation 34:02 Innovations in Sedation Techniques 36:45 Debunking Dental Myths 39:36 The Risks of DIY Dental Treatments 42:57 Understanding Local Anesthetics 44:45 Exploring Alternative Dental Practices 48:22 The Truth About Pineapple Juice and Recovery

BUFFALO, NY — May 14, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 4, on April 10, 2025, titled “Impact of Factor Xa inhibitors on cardiovascular events in older patients with nonvalvular atrial fibrillation.” In this study, first author Masahiko Takahashi and corresponding author Keisuke Okawa led a research team from Kagawa Prefectural Central Hospital and Hyogo Medical University that investigated whether Factor Xa inhibitors (Xa-Is)—a type of blood thinner—can reduce the risk of heart-related complications in patients over 80 with nonvalvular atrial fibrillation (NVAF). The study found that patients using Xa-Is experienced significantly fewer cardiovascular problems than those on other anticoagulants. This finding is especially relevant, as older adults face a high risk of both stroke and heart disease. Atrial fibrillation is a common heart rhythm disorder, particularly in the elderly, that increases the risk of blood clots, heart failure, and stroke. Anticoagulants are often prescribed to prevent clots, but not all types have the same effects on heart health. This study focused on comparing Xa-Is—specifically rivaroxaban, apixaban, and edoxaban—with commonly used drugs such as warfarin and dabigatran. Researchers followed more than 1,000 patients aged 80 and above for up to five years to assess the long-term impact of these medications on cardiovascular outcomes. Patients who used Xa-Is had significantly lower rates of heart failure, artery disease, and cardiovascular death. The risk of cardiovascular problems in the Xa-I group was less than half that of those on non-Xa-I medications. These benefits remained even after adjusting for factors like age, existing heart conditions, and kidney function. Additionally, stroke and all-cause death rates were notably lower in the Xa-I group. “Xa-Is may be useful for not only anticoagulation but also the prevention of cardiovascular events in very old patients with NVAF.” What makes Xa-Is different, according to the researchers, is their ability to inhibit a specific biological pathway—known as Factor Xa–PAR2—that contributes to inflammation, fibrosis, and damage in blood vessels and heart tissue. This effect extends beyond their traditional role in preventing blood clots. Although the study was conducted at a single medical center in Japan, its rigorous design and long follow-up period enhance the reliability of the findings for real-world clinical decision-making. While further studies, especially across multiple centers, are needed to confirm the full range of benefits, this study strongly suggests that Xa-Is may offer broader cardiovascular protection for very old patients. The findings could influence how clinicians choose blood thinners for elderly individuals with atrial fibrillation, potentially improving both survival and quality of life in this growing population. DOI - https://doi.org/10.18632/aging.206238 Corresponding author - Keisuke Okawa - k-ookawa@chp-kagawa.jp Video short - https://www.youtube.com/watch?v=YtbYpfVDVDI Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206238 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, Factor Xa inhibitor, atrial fibrillation, older patient, cardiovascular events To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

In this episode, Keith Ellis, PhD, joins Evan H. Hirsch, MD, to explore whether a herbal solution could replace triple anticoagulant therapy for Long COVID microclots.   Dr. Keith Ellis is a scientist and Associate Professor of Medicinal Chemistry who has dedicated his expertise to helping people recover from Long Covid. With a strong background in medicinal chemistry, pharmacology, and natural products, he investigates the biological mechanisms behind Long Covid and explores therapeutic pathways for recovery.   Driven by both scientific curiosity and entrepreneurial spirit, Dr. Ellis founded Science-Driven Supplements in 2023 and launched CircuGuard, a custom-formulated herbal supplement designed to support recovery from Long Covid microclots. His mission is to create natural solutions that are safe, affordable, and accessible with no prescription needed.   In parallel, Dr. Ellis continues his academic work, conducting early-stage oncology drug discovery research and teaching organic and medicinal chemistry at the graduate and undergraduate levels. His unique integration of cutting-edge science and real-world application is helping bridge the gap between research and recovery for those affected by Long Covid.   Learn more about Dr. Ellis's work at: https://keithcellisphd.com/   .   We help you resolve your Long Covid and Chronic Fatigue (ME/CFS) by finding and fixing the REAL root causes that 95% of providers miss. Learn about these causes and how we help people like you, Click Here. Do you have fatigue, brain fog, shortness of breath, muscle pain, or other strange symptoms? You might have Long Covid. Take our free quiz to find out if Long Covid is behind the mystery symptoms you're experiencing, Click Here.   For more information about Evan and his program, Click Here.   Prefer to watch on Youtube? Click Here.   Please note that any information in this episode is for educational purposes only and does not constitute medical advice.

This is the next episode of our Push Dose Pearls miniseries with ED Clinical Pharmacist, Chris Adams. In this ongoing series we'll dig into some of the questions we all have about medications we commonly see and use in the ED. In this epsidoe, we unpack the complexities of anticoagulation reversal in the emergency department - It's not just about vitamin K anymore! Tune in as we explore the key reversal agents, when and why to use them, how fast they work, and the risks that come with turning off anticoagulation. From bleeding emergencies to stroke prevention, this quick dive offers practical pearls for navigating the coagulation cascade in real time. Have you had a bad GI bleed or intracranial hemorrhage in a patient on thinners?. Share your story with us on social media or at ucdavisem.com. Hosts: Dr. Julia Magaña, Professor of Pediatric Emergency Medicine at UC Davis Dr. Sarah Medeiros, Professor of Emergency Medicine at UC Davis Guests: Christopher Adams, PharmD, Emergency Department Senior Clinical Pharmacist and former Assistant Professor at UC Davis Resources: Baugh CW, Levine M, Cornutt D, et al. Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. Ann Emerg Med. 2020 Oct;76(4):470-485. doi: 10.1016/j.annemergmed.2019.09.001. Epub 2019 Nov 13. PMID: 31732375; PMCID: PMC7393606. ACEP Point of Care Tools: Anticoagulation Reversal. **** Thank you to the UC Davis Department of Emergency Medicine for supporting this podcast and to Orlando Magaña at OM Productions for audio production services.

In this episode, we explore the crucial interaction between SSRIs and oral anticoagulants, examining a groundbreaking 23-year study of over 330,000 patients. Does combining these medications significantly increase bleeding risk, and if so, how can we safely manage patients who need both treatments? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 65 Can SSRIs Be Safely Prescribed With Oral Anticoagulants?

Laura Beaton chats with Paul Kubler, director of Rheumatology at Royal Brisbane and Women's hospital, about how to identify and manage antiphospholipid syndrome. They discuss the key presentations of APS, classification criteria and approaches to treatment. They also cover patients with catastrophic APS and asymptomatic people with persistent antiphospholipid antibodies. Read the full article by Paul and his co-authors in Australian Prescriber.

Send us a textIt's already Episode 20 of Season 2 as we roll into winter 2024.Again this week the boy's are lucky to have two Guests Bethany Keime and Charlie Kirkman, both have different heart conditions, Bathany and twin sister Hannah both suffer from Hypertropic Cardiomyopathy whilst Charlie has Arrhythmia.Hypertrophic cardiomyopathy is a condition in which muscle tissues of the heart become thickened without an obvious cause. The parts of the heart most commonly affected are the interventricular septum and the ventricles.This is  is most often caused by abnormal genes in the heart muscle. These genes cause the walls of the heart chamber (left ventricle) to become thicker than normal. The thickened walls may become stiff and this can reduce the amount of blood taken in and pumped out to the body with each heartbeat.How is hypertrophic cardiomyopathy treated?Activity limits. ...Preventing dehydration. ...Medicines to treat shortness of breath and chest pain. ...Medicines to help prevent abnormal heart rhythms. ...Anticoagulants. ...Septal myectomy. ...Alcohol septal ablation. ...Implantable cardioverter defibrillator (ICD).An Arrhythmia, or irregular heartbeat, is a problem with the rhythm or rate of your heartbeat. Your heart may beat too quickly, too slowly, or with an irregular rhythm. It is normal for your heart rate to speed up during physical activity and to slow down while resting or sleeping but with Arrhythmia this can be irregular anytime.While Arrhythmias can be a serious condition that can affect your health, there are also treatments available to help. By following a treatment plan and making heart healthy lifestyle changes, you can learn how to live with a cardiac arrhythmia.In today's Interview Bethany & Charlie tell us openly and honestly about their conditions from diagnosis to how the deal with it today and in everyday life.Bethany & sister Hannah are two remarkable twins who have taken this illness head on and realised there are others like themselves undiagnosed. Their experience as young teenagers soon discovered there was little information available and resorted to Google to explore their condition. Social Media Patient Community did not exist, so Bethany & Hannah set about correcting this by starting their own Social media presence "Heart Charged" in hope to reach out to those with this condition and those still to be diagnosed.They made us aware that as young women it was hard to get healthcare professionals to take them seriously with their health issues, simply sidelining them and saying "It's all part of growing up as a young Women"  It wasn't until a member of the family discovered they had hypertrophic cardiomyopathy that both Bethany & Hannah were then checked for this Condition.These young women have gone from strength to strength and this is how they met Charlie through Their social media connections and recent success with the "Sudden Cardiac Art" Exhibition in the UK, now destined for Southern California.#getheartcharged#charliekirkman# Stroke# Subarachnoid hemorrhage#Mediastinal Germ Cell Tumour#Prostate Cancer#Bronchiectasis#CharcotmarietoothDisease#Emphysema#The after life#Ghosts#Spirts#Ouija boards#Mediums#Psychics#Reincarnation#HeartTransplant#EbsteinsAnomaly#RareCondition#HealthJourney#LifeChangingDiagnosis#MentalHealth#Vulnerability#SelfCompassion#PostTraumaticGrowth#MedicalMiracle#BBCSports#Inspiration#Cardiology#Surgery#Podcast#HealthcareCheck out our website at www.whostomanddick.com

❤️ Bonjour,Bienvenue dans cet épisode consacré au voyage, attachez votre ceinture ✈️

In this podcast recorded in early October, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the November issue of DTB. They provide an overview of the editorial that discusses the need to support people taking drugs to help with weight loss: "Providing the drug is only one part of the process and if the other elements are not available to support people with obesity the full benefits of these expensive treatments will not be realised" - https://dtb.bmj.com/content/62/11/162. They talk about the results of an observational study that assessed the risk of major bleeds with concomitant use of selective serotonin reuptake inhibitors (SSRIs) and oral anticoagulants -  https://dtb.bmj.com/content/62/11/164. The main article discusses equity of care in the management of COPD and that those more at risk of COPD are also more likely to experience barriers to care - https://dtb.bmj.com/content/62/11/165. They begin by highlighting two articles* in the BMJ that consider the problem of conflicts of interest.   *Fabbri A, Grundy Q. Protecting early career physicians from commercial influence. BMJ. 2024 Sep 9;386:q1939. (https://www.bmj.com/content/386/bmj.q1939) McCartney M. Transparency as a means to conquer conflicts of interest is illusory. BMJ. 2024 Sep 24;386:q2092. (https://www.bmj.com/content/386/bmj.q2092)   Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.

In today's episode of Cardiology Digest, we look at three recent research papers that can impact your clinical practice. They're from NEJM Evidence, the European Heart Journal, and The New England Journal of Medicine. STUDY #1: Today's journey begins with a study examining the interplay between influenza and myocardial infarctions. Could the flu shot be more than just a seasonal precaution?   de Boer, AR, Riezebos-Brilman, A, van Hout, D, et al. 2024. Influenza infection and acute myocardial infarction. NEJM Evid. 7:EVIDoa2300361. (https://doi.org/10.1056/EVIDoa2300361) STUDY #2: Next, we wade into a cath lab debate over fasting protocols. Join us to explore research that flips traditional pre-procedure fasting requirements on their head. Are we on the brink of a new era?  Ferreira, D, Hardy, J, Meere, W, et al. 2024. Fasting vs no fasting prior to catheterisation laboratory procedures: The SCOFF trial. Eur Heart J. Published online. (https://doi.org/10.1093/eurheartj/ehae573) STUDY #3: Finally, we dig into the complexities of anticoagulation in transcatheter aortic-valve replacement patients. This study sheds light on the choice between interrupting or continuing anticoagulation, and has implications for everyday practice. van Ginkel, DJ, Bor, WL, Aarts, HM, et al. 2024. Continuation versus interruption of oral anticoagulation during TAVI. N Engl J Med. Published online. (https://doi.org/10.1056/NEJMoa2407794) Tune in for a captivating discussion that promises to enrich your clinical acumen!  Learn more with Medmastery's courses: Coronary Angiography Essentials (3 CME) Coronary Angiography Essentials Workshop (1 CME) ICD Essentials (4 CME) ICD Essentials Workshop (1 CME) Pacemaker Essentials (5 CME) Pacemaker Essentials Workshop (1 CME) Percutaneous Coronary Intervention Essentials (6 CME) Percutaneous Coronary Intervention Essentials Workshop (6 CME) Get a Basic or Pro account, or, get a Trial account. Show notes: Visit us at  https://www.medmastery.com/podcasts/cardiology-podcast.

In this episode of Medmastery's Cardiology Digest, we dive into three groundbreaking studies that are set to reshape our understanding and approach to cardiology. STUDY #1: First, we discuss a landmark piece of research that sheds new light on the benefits of percutaneous coronary intervention for patients with significant coronary artery disease who need a transcatheter aortic valve replacement. This study addresses important questions about patient selection for this intervention.   Lønborg, J, Jabbari, R, Sabbah, M, et al. 2024. PCI in patients undergoing transcatheter aortic-valve implantation. N Engl J Med. Published online. (https://doi.org/10.1056/NEJMoa2401513) STUDY #2: Next, we examine an insightful meta-analysis that evaluates patient-level data to inform the future of dual antiplatelet therapy after percutaneous coronary intervention. Discover the factors influencing the transition to ticagrelor monotherapy post-PCI and why this could change current guideline recommendations.  Valgimigli, M, Hong, S, Gragnano, F, et al. 2024. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: A systematic review and individual patient-level meta-analysis of randomized trials. Lancet. 10456: 937–948. (https://doi.org/10.1016/S0140-6736(24)01616-7) STUDY #3: Lastly, we take a closer look at the EPIC-CAD study, which aligns with previous findings from the AFIRE trial. Learn why anticoagulant monotherapy is now being considered for the majority of patients with atrial fibrillation who require anticoagulation and have stable coronary artery disease, and what this means for your clinical practice. Cho, MS, Kang, D-Y, Ahn, J-M, et al. 2024. Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease. N Engl J Med. Published online. (https://doi.org/10.1056/NEJMoa2407362) Tune in to this episode for an engaging in-depth discussion of these studies and stay ahead in the ever-evolving field of cardiology!  Learn more with Medmastery's courses: Percutaneous Coronary Intervention Essentials (6 CME) Percutaneous Coronary Intervention Essentials Workshop (6 CME) Get a Basic or Pro account, or, get a Trial account. Show notes: Visit us at  https://www.medmastery.com/podcasts/cardiology-podcast.

Témoignage consommateur de Séverine R., interviewée par Marianne lors de la Visio Nutrition Kriss-Laure du 30 Mai 2023.----  Séverine a connu Kriss-Laure par une amie, satisfaite et convaincue par les bienfaits des produits.Sujette à des soucis de circulation sanguine, Séverine décide alors de commencer à consommer Kriss-Laure régulièrement et voit rapidement des changements opérer sur elle : un meilleur sommeil, les jambes moins lourdes, une bonne récupération après ses séances sportives. Son angiologue lui a même permis d'arrêter le traitement anticoagulant qu'elle prenait depuis 20 ans, au vu des ses résultats. ----Gammes consommées : Entremets, Potage, Tonic, Krissport----Inscrivez-vous pour suivre une Visio Nutrition Kriss-Laure un lundi sur deux de 19h45 à 20h40 : https://calendly.com/kriss-laure-france/visio-nutrition-kriss-laureHébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

DISCLAMER >>>>>>    The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions.   >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests.       Disclosures: Ditch The Lab Coat podcast is produced by (Podkind.co) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University. Welcome back to "Ditch the Lab Coat," the podcast where we explore the fascinating world of health and medicine with a skeptical eye. I'm Dr. Mark Bonta and In today's episode, Dr. Kaplovitch dives deep into the different types of blood clots and the importance of personalized treatment. He explains that not all blood clots are created equal - some predominantly affect the veins, while others can travel to the lungs and become life-threatening. We discuss the various risk factors that can lead to blood clot formation, from genetic conditions to long plane rides, and Dr. Kaplovitch offers practical advice on managing this complex disorder.We also touch on the fascinating history behind some blood thinning medications, like warfarin, which was originally used as rat poison! Dr. Kaplovitch clarifies the distinctions between its toxic properties and medical use. Throughout our conversation, we emphasize the importance of transparently counseling patients about the risks and benefits of different treatments. Dr. Kaplovitch highlights the abundance of research in the field of thrombosis and how it informs the personalized approach he takes with his patients.So join us as we simplify these complex medical concepts and explore the latest advancements in blood clot prevention and treatment. As always, remember that this podcast is for informational purposes only and does not substitute for professional medical advice. Let's ditch the lab coat and dive in!04:24 Experienced medical student impresses with professionalism.09:02 Blood clots can travel to lungs, fatal.12:14 Prolonged sitting at desk may increase thrombosis risk.16:01 Minority with blood clots can improve naturally.18:45 Clot busters have significant risk of bleeding.20:59 Treatment options for preventing blood clot complications.25:39 Passion for vascular medicine, citing primary literature.29:26 Newer blood thinners may have advantages.31:37 Warfarin inhibits clotting by blocking vitamin K.36:09 Balancing blood thinness for health benefits is crucial.37:22 Maintain optimal blood thinness to prevent risks.42:22 Minor bleeding from gut might not require action.46:27 Consistent blood thinner use is crucial.50:05 Discussing evolving thrombosis practices, specifically genetic testing controversies.51:24 Testing for clotting disorders requires informed discussion.57:02 Advancements in personalized medicine revolutionize treatment.58:45 Hip hop slang reference and deep thrombosis.

Direct oral anticoagulants (DOACs) are the standard of care for stroke prevention in most patients with nonvalvular atrial fibrillation (NVAF). Data on the safety and efficacy of DOACS in patients with obesity are limited and, at times, contradictory.  What would you recommend for a patient with a BMI>40: warfarin, which requires periodic monitoring and dose adjustments, or a DOAC, which may not be as effective? Guest Authors: Taylor M. Benavides, PharmD, BCPS and Elizabeth B. Hearn, PharmD, BCACP Music by Good Talk

Braydon Dymm, MD, is a board-certified neurologist and accomplished physician who specializes in cerebrovascular disease and stroke care.After graduating summa cum laude from the University of Detroit Mercy and earning his medical degree from Wayne State University School of Medicine, he completed his neurology residency at Michigan Medicine. Dr. Dymm recently finished an advanced fellowship in cerebrovascular neurology at Duke University Hospital. He has made significant research contributions with publications in respected journals like Neurology and Stroke. Currently, Dr. Dymm serves as a neurohospitalist in the Department of Neurology at Charleston Area Medical Center.His passion for advancing stroke care and medical education has established him as an emerging leader in the field. In this episode, we cover:The differences between ischemic and hemorrhagic strokes, including causes and symptoms.The critical of recognizing stroke symptoms quickly using the BFAST mnemonic.Gender disparities in stroke incidence, with a focus on why women are more affected and have worse outcomes.The role of high blood pressure and cholesterol in stroke risk and prevention strategies.The effectiveness of exercise, diet, and stress management in reducing stroke risk.Advances in stroke treatment, including the transition from TPA to tenecteplase for quicker administration.The potential for new technologies, like continuous blood pressure monitors, to improve stroke prevention.Sign up to The Neuro Athletics Newsletter: https://bit.ly/3ewI5P0Connect with BraydonTwitter: https://x.com/BraydonDymmMy Socials:Instagram: https://www.instagram.com/louisanicola_/Twitter : https://twitter.com/louisanicola_Sponsors for today's episode:Momentous - Use code NEURO to get 20%  off your first subscription order - code NEURO:  https://www.livemomentous.com/Inside Tracker - Use code LOUISA20 for 20% off - https://insidetracker.com/louisaZocDoc- Use code NEURO - https://www.zocdoc.com/neuro(00:00) Preview and Intro(00:36) Introducing Dr. Braydon Dymm(01:08) Gender Disparities in Stroke?(02:28) Pathology of Ischemic Stroke(06:29) Small Vessel Strokes(09:56) Alzheimer's as Vascular Dementia(11:18) Managing Blood Pressure and Cholesterol(13:15) Role of Exercise in Stroke Prevention(14:22) Resistance Training and Dementia Prevention(18:13) Golden Hour in Stroke Treatment(20:07) Recognizing Stroke Symptoms with BFAST(24:47) Anticoagulants vs. Antiplatelets(25:56) Preventing Strokes with Blood Thinners(26:45) Hemorrhagic Strokes(29:36) Medication Differences for Stroke Types(32:58) Gender Differences in Stroke Outcomes(33:04) Challenges of DeThe Neuro Athletics Newsletter Instagram: @louisanicola_Twitter : @louisanicola_YouTube: @Louisa NicolaThe Neuro Experience Podcast is proud to have hosted: Dr Andrew Huberman, Dr Gabrielle Lyon, Dr Layne Norton, Thomas DeLauer, Shawn Stevenson, Dr. Rocio Salas-Whalen, Saad Alam, Uma Naidoo, Dr. Lanna Cheuck, Angela Lee Pucci, Jillian Turecki, Dr. Jordan Feigenbaum, Dr. Darren Candow, Dr. Sue Varma, Evy Poumpouras, Dr Casey Means, Renee Deehan, Dr Chris Palmer, Dr Charles Brenner.

Welcome to the latest episode of Cardiology Digest, where we chart a course through groundbreaking studies that are shaping cardiology practice!   STUDY #1: First, we discuss the nuanced world of drug interactions involving diltiazem and direct-acting oral anticoagulants like apixaban and rivaroxaban. Tune in as we scrutinize the study's limitations and practical implications for your patients with atrial fibrillation.  Ray, WA, Chung, CP, Stein, CM, et al. 2024. Serious bleeding in patients with atrial fibrillation using diltiazem with apixaban or rivaroxaban. JAMA. 18: 1565–1575. (https://jamanetwork.com/journals/jama/article-abstract/2817546) STUDY #2: Next, we turn our attention to a case-control study examining the bleeding risks associated with the combination of selective serotonin reuptake inhibitors and anticoagulants in patients with atrial fibrillation. Are the bleeding risks substantial enough to rethink this combination therapy, or are there scenarios where the benefits outweigh the dangers? We'll leave no stone unturned. Rahman, AA, Platt, RW, Beradid, S, et al. 2024. Concomitant use of selective serotonin reuptake inhibitors with oral anticoagulants and risk of major bleeding. JAMA. 3: e243208. (https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2816687) STUDY #3: Finally, we explore a fascinating meta analysis that looked at renal denervation and its long-term efficacy in controlling blood pressure. See how renal denervation stacks up against traditional antihypertensive medications and what you need to consider when thinking about incorporating it into your treatment arsenal. Sesa-Ashton, G, Nolde, JM, Muente, I, et al. 2024. Long-term blood pressure reductions following catheter-based renal denervation: A systematic review and meta-analysis. Hypertension. 6: e63–e70. (https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.123.22314) Join us to explore the potential impacts of these studies, the ongoing debates they spark within the cardiology community, and to see how these findings could influence your clinical decisions. Learn more with these courses: Atrial Fibrillation Essentials (1 CME):  Pacemaker Essentials (5 CME) Pacemaker Essentials Workshop (1 CME) Get a Basic or Pro account, or, get a Trial account. Show notes: Visit us at  https://www.medmastery.com/podcasts/cardiology-podcast.

In this episode, Dr. Serv Wahan discusses the management of patients on anticoagulants in the dental setting. He addresses common questions and concerns related to blood thinners, tranexamic acid, and the management of bleeding in dental procedures. Dr. Wahan emphasizes the importance of not stopping blood thinners and provides insights into the use of tranexamic acid for local hemostasis.   anticoagulation, blood thinners, dental procedures, tranexamic acid, local hemostasis, patient management Takeaways The importance of managing patients on blood thinners in the dental setting The use of tranexamic acid for local hemostasis in dental procedures The risks and benefits of managing patients on anticoagulants during dental surgery Titles Tranexamic Acid for Local Hemostasis in Dental Surgery Managing Patients on Anticoagulants in Dental Procedures Sound Bites "This topic is for everyone. It's not for doctors, dentists. It's for patients, it's for your family, it's for your friend." "The answer is no. I do not. We just manage any risk of bleeding locally because that's still safer than taking someone off blood thinners." "And they can use it on any cut. I just tell them, you keep it in your fridge, you can use it on any cut. You know, it's a topical. And so it does help." Chapters 00:00Introduction to Anticoagulation Management in Dentistry 03:23Local Management of Bleeding in Dental Procedures

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠Anticoagulants⁠⁠⁠⁠⁠ ⁠from the Heme section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets

Episode: D2D Edition | Deprescribing of Anticoagulants: The IF, WHEN and HOW, a Discussion with a Cardiologist Host: Sabine von Preyss-Friedman MD, FACP, CMD Guest(s): Nicole Orr, MD; Irene Hamrick MD, CMD  In This Episode: In this episode, host Sabine von Preyss-Friedman, MD, FACP, CMD, and special guests Nicole Orr, MD, and Irene Hamrick, MD, CMD, discuss the updated guidelines for ASA and deprescribing of anticoagulants.  Date Recorded: March 11, 2024 Available Credit: The American Board of Post-Acute and Long-Term Care Medicine (ABPLM) issues CMD credits for AMDA On-The-Go and affiliate podcast episodes as follows: Claim CMD Credit

When Megan Houpt made the heart-wrenching decision to pursue adoption over pregnancy due to her heart condition, it struck a chord with me as a heart mom. Together, we unfold her narrative in this episode, navigating the complexities of adoption with a CHD. From the intricate dance of home studies to the emotional synergy with a birth mother, we journey through Megan's path to motherhood. The adoption landscape can be arduous, yet it's traversed with hope and culminates in the joyous arrival of Hunter Hart, a name rich with significance. (https://www.facebook.com/HLHSMeaganHoupt)In the second segment of the podcast, we continue reading from The Heart of a Heart Warrior Volume One: Survival. This week, we complete Chapter 3: Being Active with CHD.The courage of those facing congenital heart defects takes center stage as we share stories of triumph and transformation. Hear how heart warriors like and Alicia Lynch and Megan Tones find ways to be active, despite having complex congenital heart defects.Megan takes us on an Egyptian odyssey that defies the ordinary. Imagine scaling Mount Sinai and wandering amidst ancient temples, all while balancing the intricacies of medical needs with the thrill of adventure. Her narrative captures the essence of wanderlust, peppered with humor and humanity, proving that even with health challenges, the zest for exploration knows no bounds. Alicia inspires us with her journal entries which lead us from a time of despair to a time of rejoicing.In Chapter 4: CHDs Around the GlobeAmy M. Le, Ellen Banoub, and Belen Blanton channel their battles into creating waves of change and offering a helping hand to others within the CHD community. Amy's pivot from a tech giant to a champion for indie writers, Ellen's leap from a CHD survivor to a beacon of support, and Belen's recounting of finding God's mission for her showcase the remarkable resilience and tenacity inherent in our human spirit.Join us, and let these tales of bravery, resilience, and the indomitable will to embrace life's adventures inspire you.February 2024 Baby Hearts Press announcementSupport the showAnna's Buzzsprout Affiliate LinkBaby Blue Sound CollectiveSocial Media Pages:Apple PodcastsFacebookInstagramMeWeTwitterYouTubeWebsite

Welcome to the Happy Nurse Educator podcast by nursing.com. Since 2018, nursing.com has been at the forefront of nursing education, guiding over 400,000 nursing students to academic success while helping the average student raise their lowest grade by 11.6% with an impressive 99.25% NCLEX pass rate. Download free Lesson Plans at HappyNurseEducator.com Must Know NCLEX Meds Lesson Plan Objective By the end of the lesson, the nursing student will be able to identify and understand key medications commonly encountered on the NCLEX, focusing on Analgesics, Anticonvulsants, Anti-inflammatory/Steroids, Anticoagulants, Anti-Parkinsonian drugs, Beta Blockers, Potassium supplements, Respiratory drugs, Cardiac Glycosides, Antihypertensives, Psychotropic drugs, Maternity drugs, Antifungals, Anticholinergics, Oncology medications, Anti-Gout medications, and Ophthalmic medications (miotics and mydriatics). Through this lesson, nursing students will acquire knowledge about medication classes, indications, contraindications, and essential nursing considerations. The emphasis will be on recognizing potential side effects, monitoring for complications, and understanding the rationale behind medication administration. This foundational knowledge will empower students to approach NCLEX questions with confidence and ensure safe medication practices in clinical  settings. Download free Lesson Plans at HappyNurseEducator.com  

Commentary by Dr. Mirza Umair Khalid and Dr. Bashir Alaour

Join Lisa Simon, MD, DMD (@lisathedoc) as we discuss dental care for the PCP- from examination techniques, treatment options, emergencies in dental care, and general dental advice.  Help your patients manage caries, gingivitis, dry mouth, and temporomandibular joint (TMJ) dysfunction.  Be aware of dental side effects of medications, how to manage anticoagulants during dental procedures, and when to recommend antibiotic prophylaxis.  Claim CME for this episode at curbsiders.vcu health.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Introduction and Overview 09:13 Diagnosing Dental Pain and Examination Techniques 18:44 Treatment Options for Dental Pain 29:34 Complications and Emergencies in Dental Care 32:36 Post-operative Care and General Dental Advice 40:35 Dry Mouth and Treatment Options 44:05 Gingivitis 49:39 Temporomandibular Joint (TMJ) Dysfunction 55:43 Medications and Dental Side Effects 56:12 Anticoagulants and Dental Procedures 01:00:55 Endocarditis Prophylaxis 01:03:15 Joint Replacements and Antibiotic Prophylaxis 01:04:10 Oral Health in Patients with Opioid Use Disorder Credits Written and produced, Show Notes, Infographic and Cover Art by Dr Kate Grant  Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Molly Heublein MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Lisa Simon MD, DMD Sponsor: Grammarly Go to grammarly.com/PODCAST to download for FREE today. Sponsor: Factor Head to FactorMeals.com/curb50 and use code curb50 to get 50% off.  Sponsor: Freed You can try Freed for free right now by going to freed.ai. And listeners of Curbsiders can use code CURB50 for $50 off their first month.

CME credits: 1.00 Valid until: 19-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/selecting-anticoagulants-for-acute-vte/17969/ This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.

Today we want to unravel the intricate relationship between anticoagulants and regional anesthesia. Join Garry and Terry as they navigate through the delicate balance of benefits and risks associated with these practices. We'll dive into the world of anticoagulation reversal agents, discussing FDA-approved options such as Idarucizumab and Andexanet. So join Garry and Terry as they navigate the complexities of anticoagulants and regional anesthesia, emphasizing the critical role guidelines play in ensuring patient safety in the ever-evolving landscape of anesthetic practices.   Here's some of what we discuss in this episode: The evolving perspectives on NSAIDs, COX-2 inhibitors, and aspirin, emphasizing recent data that challenges initial concerns about spinal hematomas. Neuraxial anesthesia, celebrated for positive outcomes, brings its own set of risks, notably bleeding and hematoma formation. Heparin administration, both subcutaneous and intraoperative, prompts nuanced considerations, ensuring safety in the neuraxial procedure. Insights into thrombolytic therapy, urging caution due to limited clinical data.   Visit us online and get show resources here: https://beyondthemaskpodcast.com/   Get the CE Certificate here: https://beyondthemaskpodcast.com/wp-content/uploads/2020/04/Beyond-the-Mask-CE-Cert-FILLABLE.pdf   Help us grow by leaving a review: https://podcasts.apple.com/us/podcast/beyond-the-mask-innovation-opportunities-for-crnas/id1440309246

Live Nursing Review with Regina MSN, RN! Every Monday & Wednesday we are live. LIKE, FOLLOW, & SUB @ReMarNurse for more.     Today only! Use the code: DREAM and save 50% off   Quick Facts for NCLEX Next Gen Study Guide here - https://bit.ly/QF-NGN Study with Professor Regina MSN, RN every Monday as you prepare for NCLEX Next Gen.   ► Create Free V2 Account - http://www.ReMarNurse.com ► Get Quick Facts Next Gen - https://bit.ly/QF-NGN ► Subscribe Now - http://bit.ly/ReMar-Subscription ► GET THE PODCAST: https://remarnurse.podbean.com/ ► WATCH LESSONS: http://bit.ly/ReMarNCLEXLectures/ ► FOLLOW ReMar on Instagram: https://www.instagram.com/ReMarNurse/ ► LIKE ReMar on Facebook: https://www.facebook.com/ReMarReview/   ReMar Review features weekly NCLEX review questions and lectures from Regina M. Callion MSN, RN. ReMar is the #1 content-based NCLEX review and has helped thousands of repeat testers pass NCLEX with a 99.2% student success rate! ReMar focuses on 100% core nursing content and as a result, has the best review to help nursing students to pass boards - fast!

Show notes at pharmacyjoe.com/episode884. In this episode, I ll discuss whether the reversal of anticoagulants is necessary for neurologically intact patients with traumatic intracranial hemorrhage. The post 884: Do All Patients With Traumatic ICH on Anticoagulants Need to be Reversed? appeared first on Pharmacy Joe.

Show notes at pharmacyjoe.com/episode884. In this episode, I'll discuss whether the reversal of anticoagulants is necessary for neurologically intact patients with traumatic intracranial hemorrhage. The post 884: Do All Patients With Traumatic ICH on Anticoagulants Need to be Reversed? appeared first on Pharmacy Joe.

On this podcast episode, I discuss diclofenac pharmacology, adverse effects, drug interactions, and much more. Diclofenac is one of the highest-risk NSAIDs when it comes to cardiovascular risk. You can find more information on this in the Meded101 NSAID comparison table. Diclofenac carries two boxed warnings. One is for GI bleed risk and the other is for cardiovascular risks. Anticoagulants, antiplatelets, diuretics, and ACEs/ARBs are all common medication classes that can interact with diclofenac.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Naga Chalasani, MD With the increasing incidence and prevalence of cirrhosis in patients, healthcare professionals have to routinely consider giving anticoagulants to these patients. Understanding how we can safely administer these types of medications to cirrhosis patients is important. To learn more, tune in with Dr. Peter Buch as he speaks with Dr. Naga Chalasani, Co-Author of the article, titled “The Safety of Anticoagulants and Antiplatelet Agents in Patients with Cirrhosis,” which was published in Alimentary Pharmacology and Therapeutics in November 2022, and the David W. Crabb Professor of Gastroenterology and Hepatology at Indiana University School of Medicine in Indianapolis.

It's a wrap with the anticoagulants! The DTIs some interesting fun facts especially the one that has to do with Leeches

An HRS meeting recap, Impella failure, sacubitril/valsartan, the purpose of trials, and a major breakthrough in evidence generation are the topics discussed by John Mandrola, MD in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. HRS Meeting Recap II. Impella in VT ablation - First-in-human Experience with Impella 5.0/5.5 for High-Risk Patients with Advanced Heart Failure Undergoing VT Ablationhttps://www.jacc.org/doi/10.1016/j.jacc.2023.05.012 III. Sacubitril/Valsartan ARNI Bests ARB to Reduce NT-proBNP in Stabilized Preserved-EF HF https://www.medscape.com/viewarticle/992461 - Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure https://www.jacc.org/doi/10.1016/j.jacc.2023.04.019 - Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/nejmoa1908655 - Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF https://doi.org/10.1093/eurheartj/ehad344 - Bogdan Tweet https://twitter.com/bogdienache/status/1660356776204595201?s=20 IV. Big Change in Reporting of Medical Evidence – Elan Trial - Early versus Later Anticoagulation for Stroke with Atrial Fibrillationhttps://www.nejm.org/doi/full/10.1056/NEJMoa2303048 - Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN): Protocol for an international, multicentre, randomised-controlled, two-arm, open, assessor-blinded trial https://doi.org/10.1177/23969873221106043 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact: news@medscape.net

Our amazing discoverers/scientists are always at work and in the years of 2000s they gave us this class. The other oral anticoagulants besides Warfarin. Factor 10a inhibitors part of the coagulation cascade a genius way to stop that clot. --- Support this podcast: https://podcasters.spotify.com/pod/show/wambui-wamburu/support

We continue with our oldies but goodies. Heparin was first discovered in 1916!!! Ofcourse we have improved on it since then but they all basically work the same way. Still a huge part of our treatment protocols. --- Support this podcast: https://podcasters.spotify.com/pod/show/wambui-wamburu/support

In this week's podcast, Neurology Today's editor-in-chief discusses a new study finding anticoagulants are safe for patients with atrial fibrillation and dementia, women on hormone replacement therapy had higher tau levels, and neurology residents are participants in humanities programs to foster wellness.  

Warfarin is over 60 YEARS OLD yet it's the most prescribed oral anticoagulant. Listen up, refresh yourself on this oldie but really a good goodie. --- Support this podcast: https://podcasters.spotify.com/pod/show/wambui-wamburu/support

A pre-print supports the idea of targeting microclots in long COVID patients. Also, hormonal diet drugs are the new big thing (thanks Elon and Kim Kardashian!), but a study on mice shows hormonal appetite suppressants… can have unintended sexual consequences.

A response from Jim, an important update on a potential long COVID treatment, and the question that keeps Gabe awake at night.

In this episode of the JIM Podcast, Editor-in-Chief Richard McCallum speaks with Dr. Mateo Porres-Aguilar about thrombosis and anticoagulants. Dr. Porres-Aguilar is a current Fellow of the American College of Physicians (FACP), he holds a National Board Certification of Anticoagulation Care Providers in the USA (NCBAP), is an academic Member of the International Society for Thrombosis and Heamostasis (ISTH), and he currently serves as an international representative in North America for the Mexican Society of Thrombosis and Hemostasis (SOMETH), and is part of the Latin-american chapter of Venous Thrombosis for the Latin-American Collaborative Group for Hemostasis and Thrombosis (Grupo CLAHT)

Commentary by Dr Hisaki Makimoto

This week, Rob and Zach will be talking about Anticoagulants, Thrombolytics, and Antiplatelet AgentsWe will be discussing the following topics within this episode on Anticoagulants, Thrombolytics, and Antiplatelet Agents!Hemostasis: Coagulation Cascade, Extrinsic + Intrinsic PathwayAnticoagulants:HeparinUFHLMWHFondaparinux Direct Factor InhibitorsXa Inhibitors:RivaroxabanApixabanEdoxabanThrombin Inhibitors:DabigatranArgatrobanBivalirudinVitamin K Antagonists:Warfarin (Coumadin)Thrombolytics (tPA):AlteplaseReteplaseTenecteplaseStreptokinaseUrokinaseAntiplatelets:AspirinP2y12 Receptor Blockers:ClopidogrelTicagrelorPrasugrelTiclopidineGP2b/3a Inhibitors:AbciximabEptifibatideTirofibanPDE-3 Inhibitors:CilostazolAnticoagulants, Thrombolytics, Antiplatelet Agents MOATherapeutic IndicationsAdverse Drug Reactions (ADR's)Drug ComplicationsTo follow along with Notes & Illustrations for our podcasts please become a member on our website! https://www.ninjanerd.org/podcast/anticoagulants-thrombolytics-and-antiplatelet-agentsFollow us on:YouTube: https://www.youtube.com/ninjanerdscienceInstagram: https://www.instagram.com/ninjanerdlecturesFacebook: https://www.facebook.com/NinjaNerdLecturesTwitter: https://twitter.com/ninjanerdsciDiscord: https://discord.com/invite/3srTG4dngWTikTok: https://www.tiktok.com/@ninjanerdlecturesThe Foundation of Daily Health, AG1 by Athletic GreensUnlock Your Free One Year Supply of Vitamin D3+K2 and 5 free Travel Packs Support the show

Dr. Christina Shenvi sits down with Dr. Kerstin de Wit to learn how much anticoagulation matters in terms of increasing the risk of intracranial hemorrhage after a ground-level fall.

Is nirmatrelvir-ritonavir safe to take with common heart medications? Find out about this and more in today's PV Roundup podcast.

The role of anticoagulant therapy (warfarin) with antiplatelet therapy (aspirin) is a balance of risk versus benefit. However, reducing risk by de-prescribing is often avoided due to hypothetical efficacy reduction. Join host, Geoff Wall, as he evaluates de-prescribing aspirin in patients taking anticoagulants.The GameChangerAnticoagulant therapy provides as good or better protection against vascular outcomes as aspirin – creating duplication of therapy. The increased risk of bleeds may not outweigh the negligible efficacy benefit.Are you looking for a place to network AND get some FREE CE?  Download the CEimpact app. The app allows you to connect with pharmacy professionals, get CE, attend events, access product information and so much more - all from your mobile device.Show Segments00:00 - Introductions00:58 - Aspirin Use with Anticoagulants4:02 - Overview of Schafer et al11:50 - The Gamechanger: Study Findings17:48 - Connecting to Practice: DOAC Use19:52 - Closing RemarksHostGeoff Wall, PharmD, BCPS, FCCP, CGPProfessor of Pharmacy Practice, Drake UniversityInternal Medicine/Critical Care, UnityPoint HealthReferences and ResourcesAssessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for AnticoagulationRedeem your CPE or CME hereCPE (Pharmacist)CME (Physician) Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)Pharmacists: Get a membershipPrescribers: Get a membershipCE InformationLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Discuss indications for cardioprotective aspirin in patients taking anticoagulants2. Describe drawbacks to implementing the findings of the Schaefer et al study to a general patient population using anticoagulants0.05 CEU/0.5 HrUAN: 0107-0000-22-381-H01-PInitial release date: 10/24/2022Expiration date: 10/24/2023Additional CPE and CME details can be found hereFollow CEimpact on Social Media:LinkedInInstagramDownload the CEimpact App for Free Continuing Education + so much more!

On this episode, we review the pharmacology/pharmacotherapy of anticoagulants. We compare and contrast the various agents currently available, and briefly discuss their roles in various disease states (VTE, Afib, etc).  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. To earn credit for this episode, visit the following link below to reach the post-activity test for this episode: List of accredited podcast episodes on freeCE.com For existing Unlimited freeCE members, this CE option is included in your membership benefits at no additional cost! Members can simply follow the link above to take the post-test and evaluation for this activity. Use the password BLOOD (all caps) to unlock the post-test for this episode. But if you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. CorConsult Rx listeners can save 15% off the purchase of an unlimited membership by entering the discount code “PODCAST2022” at checkout, or by clicking the following link in the description https://hubs.ly/Q012N0H60 Thanks for listening! We want to give a big thanks to our main sponsor Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. You can find our account at the website below:  www.patreon.com/corconsultrx If you have any questions for Cole or me, reach out to us on any of the following: Text - 415-943-6116 Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com Instagram and other social media platforms - @corconsultrx This podcast reviews current evidence-based medicine and pharmacy treatment options. This podcast is intended to be used for educational purposes only and is intended for healthcare professionals and students. This podcast is not for patients and not intended as advice or treatment.

Join Drs. Diurba and Folk, stellar Carolinas Medical Center Emergency Medicine Interns, and the EMGuidewire team as they discuss various reversal options for the numerous anticoagulants that exist today.

Anticoagulation in clinical practice is more common and more complicated every day. Understanding what they are, how they're used and when you'll see them in the clinical arena is critical. Two experts discuss their understanding of the landscape of anticoagulation and what you need to know about it.

Welcome to a fun filled episode about…Anticoagulants! We spend too much energy running away from understanding heparin but maybe this is the time where we lend our ears and close our eyes and talk about this genius guy/gal! What is heparin, how it works, low intensity vs high intensity drips and all the stuff we order everyday but don't sit back to think about.

After learning more about Dr. Kvist's background (01:54), the guys dive into the leeching process (12:06), Dr. Kvist's current research (21:01), and the affects of climate change on leeches (29:33). Then they reflect on life lessons derived from leeches (33:23) and the ethics of leech farming (40:51) before hearing about Dr. Kvist's favorite leechy films (45:57). We're always looking to expand our pond -- please reach out!Series URL: www.theleechpodcast.comPublic email contact: theleechpodcast@gmail.comSocial Media:@leechpodcast on Twittertheleechpodcast on InstagramExternal Links:Dr. Kvist's website [HERE]; Social Media: @sebastian_kvist on Twitter, @sebastian.kvist on IGRoyal Ontario Museum website [HERE]Credits:Hosted by Evan Cate, Banks Clark, and Aaron JonesEditing by Evan CateGraphic design by Banks ClarkOriginal music by Justin Klump of Podcast Sound and MusicProduction help by Lisa Gray of Sound Mind ProductionsEquipment help from Topher Thomas